Margaret McLoughlin - 08 Aug 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: Director
Signature: /s/ Brendan Hannah, Attorney-in-Fact for Margaret McLoughlin
Issuer symbol: QNCX
Transactions as of: 08 Aug 2023
Net transactions value: +$9,840
Form type: 4
Filing time: 09 Aug 2023, 18:18:36 UTC
Previous filing: 26 May 2023
Next filing: 07 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QNCX	Common Stock	Purchase	$9,840	+8,000		$1.23	8,000	08 Aug 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.